转移性肾细胞癌分子靶向治疗研究进展

The Development of Molecular Targeted Therapy for Metastatic Renal Cell Carcinoma

摘要: 肾细胞癌是泌尿系统肿瘤中常见的恶性肿瘤,发病率约5～10/10万。转移性肾细胞癌在以细胞因子为基础的治疗失败后,尚无明确的二线治疗措施。随着对乏氧诱导因子(hypoxia-inducible factor,HIF)相关蛋白的研究,转移性肾细胞癌分子靶向治疗研究成为热点。本文综述较有前景的靶向药物,包括Bevacizumab(贝伐单抗)、Sorafenib(索拉非尼)、Sunitinib(舒尼替尼)、AG-013736、Vatalanib(PTK787)、Thalidomide(沙利度胺)及Temsirolimus(CCI-779)。

Abstract: Renal cell cancer (RCC) is the common urological cancer with an incidence of approxi-mate 5 to 10 per 100 000. There was no established second- line therapy, after failure of the cytokine-based therapy on the patients with metastatic renal cell cancer. With a progress of the studies on hypox-ia- inducible factor (HIF)- related protein, study of the molecular targeted therapy for metastatic RCC has become a hot spot. Some of the promising therapeutics investigated in this research include , vata-lanib (PTK787), sunitinib (Sutent, SU11248), AG- 013736, sorafenib (BAY 43- 9006), thalidomide and temsirolimus (CCI- 779).